# Addex Therapeutics Ltd.: financial statements, quarterly

ADXN · Nasdaq · CIK 1574232 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adxn.md) · [Financials](/companies/adxn/financials.md) · [Filings](/companies/adxn/filings.md) · [Insiders](/companies/adxn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/adxn/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2016-12-31) | period not labelled (2017-12-31) | period not labelled (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.4](/filings/0001047469-20-002580.md) | [2.6](/filings/0001047469-21-000566.md) | [31.5](/filings/0001104659-23-038581.md) | [31.5](/filings/0001104659-22-032171.md) | [18.7](/filings/0001104659-24-048532.md) | [20.5](/filings/0001104659-25-049380.md) | [7.0](/filings/0001104659-25-049380.md) | [3.9](/filings/0001104659-25-049380.md) | [3.3](/filings/0001104659-25-049380.md) |
| Current assets | $m | not reported | not reported | [42.2](/filings/0001047469-20-002580.md) | [32.4](/filings/0001047469-21-000566.md) | [19.5](/filings/0001104659-22-032171.md) | [21.9](/filings/0001104659-23-038581.md) | [7.8](/filings/0001104659-24-048532.md) | [4.2](/filings/0001104659-25-049380.md) | [3.5](/filings/0001104659-25-049380.md) |
| Total assets | $m | not reported | not reported | [42.2](/filings/0001047469-20-002580.md) | [33.0](/filings/0001047469-21-000566.md) | [20.2](/filings/0001104659-22-032171.md) | [22.5](/filings/0001104659-23-038581.md) | [8.3](/filings/0001104659-24-048532.md) | [4.6](/filings/0001104659-25-049380.md) | [10.7](/filings/0001104659-25-049380.md) |
| Current liabilities | $m | not reported | not reported | [2.3](/filings/0001047469-20-002580.md) | [5.7](/filings/0001047469-21-000566.md) | [3.6](/filings/0001104659-22-032171.md) | [4.1](/filings/0001104659-23-038581.md) | [3.3](/filings/0001104659-24-048532.md) | [2.9](/filings/0001104659-25-049380.md) | [0.8](/filings/0001104659-25-049380.md) |
| Shareholders' equity | $m | [0.2](/filings/0001047469-20-002580.md) | [1.3](/filings/0001047469-21-000566.md) | [39.2](/filings/0001104659-22-032171.md) | [25.5](/filings/0001104659-23-038581.md) | [14.6](/filings/0001104659-24-048532.md) | [16.9](/filings/0001104659-25-049380.md) | [4.9](/filings/0001104659-25-049380.md) | [1.1](/filings/0001104659-25-049380.md) | [9.7](/filings/0001104659-25-049380.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 147,831,814 at 2025-12-31, from the cover of the [20-F filed 2026-05-15](/filings/0001104659-26-062447.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.